Eton Pharmaceuticals, INC. 8-K Filing
Ticker: ETON · Form: 8-K · Filed: Dec 4, 2025 · CIK: 1710340
Sentiment: neutral
Filing Stats: 509 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-12-04 07:30:23
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20251203_8k.htm (8-K) — 26KB
- ex_895126.htm (EX-99.1) — 19KB
- a01.jpg (GRAPHIC) — 136KB
- a02.jpg (GRAPHIC) — 160KB
- a03.jpg (GRAPHIC) — 120KB
- a04.jpg (GRAPHIC) — 127KB
- a05.jpg (GRAPHIC) — 203KB
- a06.jpg (GRAPHIC) — 131KB
- a07.jpg (GRAPHIC) — 182KB
- a08.jpg (GRAPHIC) — 100KB
- a09.jpg (GRAPHIC) — 146KB
- a10.jpg (GRAPHIC) — 150KB
- a11.jpg (GRAPHIC) — 144KB
- a12.jpg (GRAPHIC) — 115KB
- a13.jpg (GRAPHIC) — 81KB
- a14.jpg (GRAPHIC) — 145KB
- a15.jpg (GRAPHIC) — 146KB
- a16.jpg (GRAPHIC) — 169KB
- a17.jpg (GRAPHIC) — 156KB
- a18.jpg (GRAPHIC) — 115KB
- a19.jpg (GRAPHIC) — 180KB
- a20.jpg (GRAPHIC) — 207KB
- a21.jpg (GRAPHIC) — 145KB
- a22.jpg (GRAPHIC) — 150KB
- a23.jpg (GRAPHIC) — 145KB
- a24.jpg (GRAPHIC) — 133KB
- a25.jpg (GRAPHIC) — 148KB
- a26.jpg (GRAPHIC) — 199KB
- a27.jpg (GRAPHIC) — 135KB
- a28.jpg (GRAPHIC) — 146KB
- a29.jpg (GRAPHIC) — 122KB
- a30.jpg (GRAPHIC) — 180KB
- a31.jpg (GRAPHIC) — 94KB
- 0001437749-25-036853.txt ( ) — 6369KB
- eton-20251204.xsd (EX-101.SCH) — 3KB
- eton-20251204_def.xml (EX-101.DEF) — 11KB
- eton-20251204_lab.xml (EX-101.LAB) — 15KB
- eton-20251204_pre.xml (EX-101.PRE) — 11KB
- eton20251203_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 4, 2025, members of the Eton Pharmaceuticals, Inc. management team will be attending the Piper Sandler Annual Healthcare Conference in New York, NY, and will present the corporate slide presentation attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference, at the conference as well in meetings with investors and other parties during the conference. The information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit 99.1 Eton Pharmaceuticals, Inc. Corporate Presentation dated December 4, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 4, 2025 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 3